Anti-Fibrinolytic Drugs - Gambia

Gambia

The projected revenue for the Anti-Fibrinolytic Drugs market in Gambia is expected to reach US$86.30k in 2024.
The market is projected to grow at an annual growth rate (CAGR 2024-2029) of 4.74%, which will result in a market volume of US$108.80k by 2029.
In terms of global comparison, United States is expected to generate the highest revenue in the market, with a projected revenue of US$9,858.00m in 2024.
Gambia's pharmaceutical market for anti-fibrinolytic drugs is experiencing a significant increase in demand due to the rise in cardiovascular diseases among its population.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Gambia has been experiencing steady growth in recent years.

Customer preferences: Patients in Gambia who suffer from bleeding disorders such as hemophilia or women with menorrhagia are the primary consumers of Anti-Fibrinolytic Drugs. These drugs work by preventing the breakdown of blood clots, thereby reducing the risk of excessive bleeding.

Trends in the market: The Anti-Fibrinolytic Drugs market in Gambia has been growing as a result of increased awareness of bleeding disorders and the availability of these drugs. The government and non-governmental organizations have been working to improve access to healthcare services and have been providing funding for the treatment of bleeding disorders. This has led to an increase in demand for Anti-Fibrinolytic Drugs.

Local special circumstances: Gambia is a small country with a population of approximately 2 million people. The healthcare system in Gambia is underdeveloped, and there is a shortage of healthcare professionals and medical facilities. This has led to challenges in the distribution and availability of Anti-Fibrinolytic Drugs. However, the government and non-governmental organizations have been working to address these challenges by investing in healthcare infrastructure and training healthcare professionals.

Underlying macroeconomic factors: The economy of Gambia is heavily dependent on agriculture, and the country has a high poverty rate. The government has been working to diversify the economy and reduce poverty through initiatives such as the National Development Plan. However, the country still faces significant challenges in terms of economic development and healthcare provision. The growth of the Anti-Fibrinolytic Drugs market in Gambia is therefore an important development in the country's healthcare sector.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.